Antidiabetic
Phase 2Small molecule
Antidiabetic is one of 166 small molecule programs targeting Cognitive impairment. It is currently in Phase 2.
5
Indications
5
Total Trials
1
Active Trials
165
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Antidiabetic
FFederico II University
Phase 2
Toradol
RochePreclinical
Cataflam
NovartisPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Paracetamol
GSKPreclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Heart Failure1 trial
Diabetic Nephropathy1 trial
Magnesium Supplementation in Diabetic Nephropathy
Completed·—·Phase 2·NCT03824379·60 enrolled
Non-Alcoholic Fatty Liver Disease1 trial
Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
Completed·—·Phase 2·NCT03850886·61 enrolled
Osteoarthritis1 trial
GLP1 Analogues and the Risk of Osteoarthritis
Not yet recruiting·—··NCT07360457·390 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antidiabetic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFederico II University